A meta-analysis of PD-L1 expression and response to checkpoint inhibitor therapy confirmed a better overall survival and tumor response in HNSCC patients with high PD-L1 expression [24]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.